Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR-HCM
KCT0009434Phase 4Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in hypertrophic cardiomyopathy (HCM), sponsored by Daewoong Pharmaceutical. Planned start May 2024; status: not yet recruiting.
02
Drugs
enavogliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on KCT0009434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009434.